Yamagata University School of Medicine, Department of Obstetrics and Gynecology, Yamagata, Japan.
Tohoku J Exp Med. 2011 Feb;223(2):91-6. doi: 10.1620/tjem.223.91.
Pseudomyxoma peritonei (PMP) is a rare condition of mucinous ascites associated mainly with mucinous tumors of appendix or ovary. PMP often recurs after treatment and may eventually cause death by abdominal visceral dysfunction via compression with mucinous ascites. Although radical peritonectomy and hyperthermic intra-peritoneal chemotherapy are becoming popular globally, the optimal treatment of PMP has not been established in Japan. We conducted a retrospective multicenter study to clarify the optimal treatment and the prognostic factors of PMP. A total of 23 patients with PMP were analyzed in the Tohoku Gynecologic Cancer Unit (TGCU). Clinical and follow-up data were retrieved and a central pathology review was performed. The median follow-up period was 46 months. Eleven patients underwent complete resection. There were 7 deaths out of 13 recurrences/progressions in this period. All the recurrence/progression was confined to the abdomen. Unexpectedly, neither radical peritonectomy nor hyperthermic intra-peritoneal chemotherapy had been performed, indicating that both radical peritonectomy and hyperthermic intra-peritoneal chemotherapy are not yet popular in Japan. The medians of overall survival and disease-free period were 166 months and 30 months, respectively. Univariate and multivariate analyses revealed that the only prognostic factor was macroscopic residual tumor (P=0.022). Although chemotherapy was not a prognostic factor (P=0.16), those who received intra-peritoneal chemotherapy tended to have a better prognosis than those who received systemic or no chemotherapy (P=0.064). In conclusion, the macroscopic residual tumor is an important prognostic factor in Japanese patients with PMP.
腹膜假性黏液瘤(PMP)是一种罕见的黏液性腹水伴发疾病,主要与阑尾或卵巢的黏液性肿瘤相关。PMP 经治疗后常复发,最终可能因黏液性腹水导致腹腔内脏器功能障碍而死亡。虽然根治性腹膜切除术和腹腔内热灌注化疗在全球范围内日益普及,但日本尚未确立 PMP 的最佳治疗方法。我们进行了一项回顾性多中心研究,旨在阐明 PMP 的最佳治疗方法和预后因素。在东北妇科癌症组(TGCU)共分析了 23 例 PMP 患者。检索了临床和随访数据,并进行了中心病理复查。中位随访时间为 46 个月。11 例患者行完全切除术。在此期间,13 例复发/进展中有 7 例死亡。所有复发/进展均局限于腹部。出乎意料的是,根治性腹膜切除术和腹腔内热灌注化疗均未进行,表明这两种方法在日本尚未普及。总生存期和无病生存期的中位数分别为 166 个月和 30 个月。单因素和多因素分析显示,唯一的预后因素是肉眼残留肿瘤(P=0.022)。虽然化疗不是预后因素(P=0.16),但接受腹腔内化疗的患者预后似乎优于接受全身化疗或未接受化疗的患者(P=0.064)。总之,肉眼残留肿瘤是日本 PMP 患者的一个重要预后因素。